Cyclacel Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 69.9% and 79.1% per annum respectively while EPS is expected to grow by 69.1% per annum.

Informazioni chiave

69.9%

Tasso di crescita degli utili

69.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.1%
Tasso di crescita dei ricavi	79.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	23 Oct 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CYCC.P - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	0	-16	N/A	N/A	1
12/31/2025	0	-15	N/A	N/A	1
12/31/2024	0	-13	N/A	N/A	1
6/30/2024	0	-18	-12	-12	N/A
3/31/2024	0	-20	-10	-10	N/A
12/31/2023	0	-23	-16	-16	N/A
9/30/2023	0	-25	-17	-17	N/A
6/30/2023	0	-24	-20	-20	N/A
3/31/2023	N/A	-23	-21	-21	N/A
12/31/2022	N/A	-21	-21	-21	N/A
9/30/2022	N/A	-19	-20	-20	N/A
6/30/2022	N/A	-19	-19	-19	N/A
3/31/2022	N/A	-20	-22	-22	N/A
12/31/2021	N/A	-19	-19	-19	N/A
9/30/2021	N/A	-20	-15	-15	N/A
6/30/2021	N/A	-18	-11	-11	N/A
3/31/2021	N/A	-15	-9	-9	N/A
12/31/2020	N/A	-12	-8	-8	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-8	-8	-8	N/A
3/31/2020	N/A	-7	-9	-9	N/A
12/31/2019	N/A	-8	-9	-9	N/A
9/30/2019	0	-8	-10	-10	N/A
6/30/2019	0	-8	-9	-9	N/A
3/31/2019	0	-8	-8	-8	N/A
12/31/2018	0	-7	-7	-7	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-14	-7	-7	N/A
3/31/2018	N/A	-15	N/A	-6	N/A
12/31/2017	N/A	-15	N/A	-7	N/A
9/30/2017	0	-16	N/A	-8	N/A
6/30/2017	0	-10	N/A	-10	N/A
3/31/2017	1	-11	N/A	-11	N/A
12/31/2016	1	-12	N/A	-10	N/A
9/30/2016	1	-13	N/A	-10	N/A
6/30/2016	1	-12	N/A	-11	N/A
3/31/2016	2	-13	N/A	-13	N/A
12/31/2015	2	-15	N/A	-14	N/A
9/30/2015	2	-16	N/A	-15	N/A
6/30/2015	2	-18	N/A	-18	N/A
3/31/2015	2	-20	N/A	-19	N/A
12/31/2014	2	-20	N/A	-19	N/A
9/30/2014	2	-18	N/A	-20	N/A
6/30/2014	1	-19	N/A	-16	N/A
3/31/2014	1	-13	N/A	-18	N/A
12/31/2013	1	-20	N/A	-18	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: CYCC.P is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Guadagni vs Mercato: CYCC.P is forecast to become profitable over the next 3 years, which is considered above average market growth.

Guadagni ad alta crescita: CYCC.P is expected to become profitable in the next 3 years.

Ricavi vs Mercato: CYCC.P's revenue (79.1% per year) is forecast to grow faster than the US market (8.9% per year).

Ricavi ad alta crescita: CYCC.P's revenue (79.1% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if CYCC.P's Return on Equity is forecast to be high in 3 years time

Cyclacel Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Cyclacel Pharmaceuticals, Inc Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Cyclacel Pharmaceuticals Receives Subsequent Non-Compliance Notice from Nasdaq Regarding Nasdaq Listing Rule 5550(b)(1)

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as Precision Medicine for Cancer

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding

Cyclacel Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Related to Shareholder's Equity

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Cyclacel Pharmaceuticals, Inc. Announces Board Changes

Cyclacel Pharmaceuticals, Inc. Announces Executive Changes

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.525241 million.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Receives a Written Notice from the Nasdaq Stock Market

Cyclacel Pharmaceuticals, Inc. announced delayed 10-Q filing

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Cyclacel Pharmaceuticals, Inc. Appoints Kenneth M. Ferguson as a Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients with Advanced Solid Tumors and Lymphomas

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients with Advanced Solid Tumors and Aggressive Lymphomas

Cyclacel Pharmaceuticals Announces Management Changes

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Cyclacel Pharmaceuticals Announces the Election of Brian Schwartz, M.D. to Its Board of Directors

Cyclacel Pharmaceuticals, Inc. Appoints Karin L. Walker as Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 11, 2020

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients with Advanced Solid Tumors At the EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita